Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.

NCT02595281 is registered in ClinicalTrials.gov with Institut de Cancérologie de Lorraine as lead sponsor.

NCT NCT02595281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.
Lead sponsor
Institut de Cancérologie de Lorraine
Phase
Not applicable
Overall status
Completed
Start date
April 1, 2016
Completion date
July 18, 2022
Enrollment
90 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian carcinoma